Current Insights on Vaccines available for COVID-19 like Flu Symptoms

Author:

Singh Abhishek1,Nimisha Nimisha1,Singh Niharika1,Gupta Rishabh1

Affiliation:

1. Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313.

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused pandemic with a rapid spread and became a major public health issue in the world in year 2020. A potentially lethal illness known as coronavirus disease-2019 was produced by this novel coronavirus member (COVID-19). Combatingthe COVID-19/SARS-CoV2 epidemic, which is endangering the foundation of our civilization, resulting in horrific human casualties, and placing a massive economic burden on the whole world, has presented us with an unparalleled task. The creation of novel testing kits and treatment stoco mbatthe pandemic, including the creation of portable, quicklydeployable, and cost-effective diagnostic testing kits, personal protective equipment, mechanical ventilators, vaccines, and data analysis and modelling tools, has become urgently necessary during this trying time. The vaccination of the populace is acknowledged as a public health priority in the current setting of the epidemic caused by SARS-COV-2. The genomic sequencing for SARS-COV2 was completed fast, in just one month. Since then, vaccination has been the focus of research on a global scale. The pandemic has compelled scientists across the globe to research solutions for treatments as well as vaccines to stop COVID-19. Various researches on SARS-CoV and, to a lesser degree, MERS have provided guidance about immunisation tactics regarding this unique coronavirus. It is explained by the statement that the SARS-CoV-2 shares 79% genetic similarity with SARS-CoV and uses human Angiotensin Converting Enzyme 2 (hACE2) receptor on the host cell. There are several platforms for developing vaccines, including virus-vectored vaccines, m-RNA based vaccines, protein subunit vaccines, m-RNA based nanotherapeutics, intranasal vaccines, recombinant spike protein vaccines, self-amplifying m-RNA vaccines and monoclonal antibodies for passive immunisation that are being evaluated for COVID-19. All these platforms have certain pros and cons. The COVID-19 pandemic is possibly the second most deadly in the last century after the Spanish flu that requires a quick assessment of the various target efficacies in inducing immunity in preventing unplanned immune-potentiation. This article aims to give readers a detailed insight intovaccines that will be successful against the new coronavirus that has ravaged the global economy, human health, and quality of life.

Publisher

A and V Publications

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3